WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Altin, SedatHas files: Yes

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    COVID-19 Pandemic and the Global Perspective of Turkish Thoracic Society
    (AVES, 2020-01-01) Kokturk, Nurdan; Itil, Bahriye Oya; Altinisik, Goksel; Adiguzel, Nalan; Akgun, Metin; Akyildiz, Levent; Altin, Sedat; Arikan, Huseyin; Ates, Gungor; Ay, Pinar; Aykac, Nilufer; Babayigit, Cenk; Bostan, Pinar; Cinel, Guzin; Calisir, Haluk Celaleddin; Celik, Pinar; Cetinkaya, Pelin Duru; Dagli, Elif; Demir, Ahmet Ugur; Demir, Canan; Dikensoy, Oner; Edis, Ebru Cakir; Elbek, Osman; Erdinc, Munevver; Ergan, Begum; Eyuboglu, A. Fusun Oner; Gemicioglu, Bilun; Goksel, Tuncay; Gulhan, Erkmen; Gultekin, Okkes; Gurkan, Canan Gunduz; Gurgun, Alev; Havlucu, Yavuz; Basoglu, Ozen K.; Karakurt, Sait; Karkurt, Zuhal; Kilinc, Oguz; Kocabas, Ali; Kul, Seval; Musellim, Benan; Nayci, Sibel; Ozkan, Metin; Pinarer, Ozgun; Salturk, Cuneyt; Sandal, Abdulsamet; Sayiner, Abdullah; Sen, Elif; Simsek, Gokcen Omeroglu; Karadag, Bulent Taner; Akyil, Fatma Tokgoz; Toreyin, Zehra Nur; Ucan, Eyup Sabri; Kucuk, Filiz Cagla Uyanusta; Varol, Ayhan; Yasin, Yesim; Yildiz, Tekin; Yorgancioglu, A. Arzu; Bayram, Hasan; Foll, Turkish Thoracic Soc C. O. V. I. D.-19
    It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions.
  • Thumbnail Image
    Item
    The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients
    (W B SAUNDERS CO LTD, 2021-01-01) Kokturk, Nurdan; Babayigit, Cenk; Kul, Seval; Cetinkaya, Pelin Duru; Nayci, Sibel Atis; Baris, Serap Argun; Karcioglu, Oguz; Aysert, Pinar; Irmak, Ilim; Yuksel, Aycan Akbas; Sekibag, Yonca; Toprak, Oya Baydar; Azak, Emel; Mulamahmutoglu, Sait; Cuhadaroglu, Caglar; Demirel, Aslihan; Kerget, Bugra; Ketencioglu, Burcu Baran; Ozger, Hasan Selcuk; Ozkan, Gulcihan; Ture, Zeynep; Ergan, Begum; Oguz, Vildan Avkan; Kilinc, Oguz; Ercelik, Merve; Ciftci, Tansu Ulukavak; Alici, Ozlem; Temel, Esra Nurlu; Ataoglu, Ozlem; Aydin, Asena; Bahcetepe, Dilek Cetiner; Gullu, Yusuf Taha; Fakili, Fusun; Deveci, Figen; Kose, Neslihan; Tor, Muge Meltem; Gunluoglu, Gulsah; Altin, Sedat; Turgut, Teyfik; Tuna, Tibel; Ozturk, Onder; Dikensoy, Oner; Gulhan, Pinar Yildiz; Basyigit, Ilknur; Boyaci, Hasim; Oguzulgen, I. Kivilcim; Borekci, Sermin; Gemicioglu, Bilun; Bayraktar, Firat; Elbek, Osman; Hanta, Ismail; Okur, Hacer Kuzu; Sagcan, Gulseren; Uzun, Oguz; Akgun, Metin; Altinisik, Goksel; Dursun, Berna; Edis, Ebru Cakir; Gulhan, Erkmen; Eyuboglu, Fusun Oner; Gultekin, Okkes; Havlucu, Yavuz; Ozkan, Metin; Coskun, Aysin Sakar; Sayiner, Abdullah; Kalyoncu, Ali Fuat; Itil, Oya; Bayram, Hasan
    The COVID-19-related death rate varies between countries and is affected by various risk factors. This multi-center registry study was designed to evaluate the mortality rate and the related risk factors in Turkey. We retrospectively evaluated 1500 adults with COVID-19 from 26 centers who were hospitalized between March 11 and July 31, 2020. In the study group, 1041 and 459 cases were diagnosed as definite and highly probable cases, respectively. There were 993 PCR-positive cases (66.2\%). Among all cases, 1144 (76.3\%) were diagnosed with non-severe pneumonia, whereas 212 (14.1\%) had severe pneumonia. Death occurred in 67 patients, corresponding to a mortality rate of 4.5\% (95\% CI:3.5-5.6). The univariate analysis demonstrated that various factors, including male sex, age >= 65 years and the presence of dyspnea or confusion, malignity, chronic obstructive lung disease, interstitial lung disease, immunosuppressive conditions, severe pneumonia, multiorgan dysfunction, and sepsis, were positively associated with mortality. Favipiravir, hydroxychloroquine and azithromycin were not associated with survival. Following multivariate analysis, male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were found to be independent risk factors for mortality. Among the biomarkers, procalcitonin levels on the 3rd-5th days of admission showed the strongest associations with mortality (OR: 6.18
  • Thumbnail Image
    Item
    The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort
    (FRONTIERS MEDIA SA, 2022-01-01) Babayigit, Cenk; Kokturk, Nurdan; Kul, Seval; Cetinkaya, Pelin Duru; Nayci, Sibel Atis; Baris, Serap Argun; Karcioglu, Oguz; Aysert, Pinar; Irmak, Ilim; Yuksel, Aycan Akbas; Sekibag, Yonca; Toprak, Oya Baydar; Azak, Emel; Mulamahmutoglu, Sait; Cuhadaroglu, Caglar; Demirel, Aslihan; Kerget, Bugra; Ketencioglu, Burcu Baran; Ozger, Hasan Selcuk; Ozkan, Gulcihan; Ture, Zeynep; Ergan, Begum; Oguz, Vildan Avkan; Kilinc, Oguz; Ercelik, Merve; Ciftci, Tansu Ulukavak; Alici, Ozlem; Temel, Esra Nurlu; Ataoglu, Ozlem; Aydin, Asena; Bahcetepe, Dilek Cetiner; Gullu, Yusuf Taha; Fakili, Fusun; Deveci, Figen; Kose, Neslihan; Tor, Muge Meltem; Gunluoglu, Gulsah; Altin, Sedat; Turgut, Teyfik; Tuna, Tibel; Ozturk, Onder; Dikensoy, Oner; Gulhan, Pinar Yildiz; Basyigit, Ilknur; Boyaci, Hasim; Oguzulgen, Ipek Kivilcim; Borekci, Sermin; Gemicioglu, Bilun; Bayraktar, Firat; Elbek, Osman; Hanta, Ismail; Kuzu Okur, Hacer; Sagcan, Gulseren; Uzun, Oguz; Akgun, Metin; Altinisik, Goksel; Dursun, Berna; Edis, Ebru Cakir; Gulhan, Erkmen; Eyuboglu, Fusun Oner; Gultekin, Okkes; Havlucu, Yavuz; Ozkan, Metin; Coskun, Aysin; Sayiner, Abdullah; Kalyoncu, A. Fuat; Itil, Oya; Bayram, Hasan
    Background and objectivesAlthough several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. MethodsPatients admitted to 26 different hospitals located in 16 different provinces between March 11-July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. ResultsWe retrospectively evaluated 1,472 COVID-19 adult patients
  • Thumbnail Image
    Item
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
    (ELSEVIER SCIENCE INC, 2021-01-01) Tanriover, Mine Durusu; Doganay, Hamdi Levent; Akova, Murat; Guner, Hatice Rahmet; Azap, Alpay; Akhan, Sila; Kose, Sukran; Erdinc, Fatma Sebnem; Akalin, Emin Halis; Tabak, Omer Fehmi; Pullukcu, Husnu; Batum, Ozgur; Yavuz, Serap Simsek; Turhan, Ozge; Yildirmak, Mustafa Taner; Koksal, Iftihar; Tasova, Yesim; Korten, Volkan; Yilmaz, Gurdal; Celen, Mustafa Kemal; Altin, Sedat; Celik, Ilhami; Bayindir, Yasar; Karaoglan, Ilkay; Yilmaz, Aydin; Ozkul, Aykut; Gur, Hazal; Unal, Serhat; Grp, CoronaVac Study
    Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. Methods This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 mu g inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0.5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. Findings Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 {[}65.1\%] in the vaccine group and 3568 {[}34.9\%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 {[}65.4\%] and 3470 {[}34.6\%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36-48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (31.7 cases {[}14.6-59.3] per 1000 person-years) and 32 cases were reported in the placebo group (192.3 cases {[}135.7-261.1] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 83.5\% (95\% CI 65.4-92.1